Stock 3320 CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials China Resources Pharmaceutical Group Limited

Equities

3320

HK0000311099

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:07 09/05/2024 BST 		5-day change 1st Jan Change
5.58 HKD +5.48% Intraday chart for China Resources Pharmaceutical Group Limited +9.84% +8.77%
04-24 China Resources Pharmaceutical Group Limited Announces Change of Company Secretary CI
04-18 China Resources Pharma Unit Issues 3 Billion Yuan Bonds MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 45,437 25,004 22,303 39,705 32,229 35,056 - -
Enterprise Value (EV) 1 74,178 57,928 61,337 73,426 68,431 68,125 66,651 61,617
P/E ratio 13.9 x 7.65 x 5.92 x 9.58 x 8.41 x 7.83 x 6.93 x 6.5 x
Yield 1.52% 3.02% 4.23% 2.53% 3% 2.95% 3.31% 3.49%
Capitalization / Revenue 0.22 x 0.12 x 0.09 x 0.16 x 0.13 x 0.13 x 0.11 x 0.1 x
EV / Revenue 0.36 x 0.29 x 0.26 x 0.29 x 0.28 x 0.24 x 0.21 x 0.18 x
EV / EBITDA 5.9 x 4.91 x 4.83 x 4.38 x 4.82 x 4.16 x 3.67 x 3.24 x
EV / FCF 11.3 x 8.86 x 5.88 x 7.47 x - 13.1 x 9.78 x 6.82 x
FCF Yield 8.82% 11.3% 17% 13.4% - 7.62% 10.2% 14.7%
Price to Book 1.12 x 0.54 x 0.44 x 0.8 x 0.35 x 0.68 x 0.6 x 0.54 x
Nbr of stocks (in thousands) 6,284,506 6,282,510 6,282,510 6,282,510 6,282,510 6,282,510 - -
Reference price 2 7.230 3.980 3.550 6.320 5.130 5.580 5.580 5.580
Announcement Date 30/03/20 26/03/21 29/03/22 30/03/23 26/03/24 - - -
1HKD in Million2HKD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 204,454 200,423 236,806 254,106 244,704 280,273 311,708 340,564
EBITDA 1 12,576 11,790 12,690 16,775 14,191 16,364 18,182 19,035
EBIT 1 10,212 9,346 9,868 13,623 11,027 13,524 14,814 15,886
Operating Margin 4.99% 4.66% 4.17% 5.36% 4.51% 4.83% 4.75% 4.66%
Earnings before Tax (EBT) 1 6,640 7,076 8,408 9,856 9,880 11,585 12,932 14,152
Net income 1 3,286 3,297 3,769 4,147 3,854 4,575 5,118 5,442
Net margin 1.61% 1.65% 1.59% 1.63% 1.58% 1.63% 1.64% 1.6%
EPS 2 0.5200 0.5200 0.6000 0.6600 0.6100 0.7129 0.8057 0.8590
Free Cash Flow 1 6,544 6,537 10,428 9,833 - 5,191 6,817 9,035
FCF margin 3.2% 3.26% 4.4% 3.87% - 1.85% 2.19% 2.65%
FCF Conversion (EBITDA) 52.04% 55.45% 82.17% 58.62% - 31.72% 37.49% 47.47%
FCF Conversion (Net income) 199.13% 198.27% 276.68% 237.09% - 113.47% 133.2% 166.02%
Dividend per Share 2 0.1100 0.1200 0.1500 0.1600 0.1540 0.1648 0.1845 0.1945
Announcement Date 30/03/20 26/03/21 29/03/22 30/03/23 26/03/24 - - -
1HKD in Million2HKD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 102,531 89,387 111,036 114,488 122,319 125,716 128,390 138,940 105,764 143,963 128,572 160,464 143,838
EBITDA - - 4,573 - - - - - - - - - -
EBIT 1 - - 3,711 6,481 4,058 7,822 5,801 7,745 3,282 8,513 5,269 9,761 5,277
Operating Margin - - 3.34% 5.66% 3.32% 6.22% 4.52% 5.57% 3.1% 5.91% 4.1% 6.08% 3.67%
Earnings before Tax (EBT) - - 2,586 - - - - 7,117 2,763 - - - -
Net income - - 719.9 - - - - 3,038 816.2 - - - -
Net margin - - 0.65% - - - - 2.19% 0.77% - - - -
EPS 2 0.0400 0.4100 0.1100 0.3900 0.2100 0.4800 0.1800 - 0.1300 0.4900 0.2100 0.5600 0.1900
Dividend per Share - - - - - - - - - - - - -
Announcement Date 30/03/20 27/08/20 26/03/21 25/08/21 29/03/22 25/08/22 30/03/23 31/08/23 26/03/24 - - - -
1HKD in Million2HKD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 28,741 32,924 39,035 33,720 36,202 33,068 31,594 26,561
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.285 x 2.792 x 3.076 x 2.01 x 2.551 x 2.021 x 1.738 x 1.395 x
Free Cash Flow 1 6,544 6,537 10,428 9,833 - 5,191 6,817 9,035
ROE (net income / shareholders' equity) 8.21% 7.56% 7.73% 8.25% 8.61% 8.47% 8.75% 8.23%
ROA (Net income/ Total Assets) 1.8% 1.65% 1.65% 1.69% 1.67% 2.3% 2.4% 2.3%
Assets 1 183,087 199,693 228,973 244,931 231,152 199,308 213,439 236,776
Book Value Per Share 2 6.480 7.400 8.110 7.890 14.80 8.220 9.300 10.30
Cash Flow per Share 2 1.910 2.140 2.040 5.140 - 2.000 1.280 1.340
Capex 1 1,597 1,669 2,415 2,798 - 3,446 3,946 4,057
Capex / Sales 0.78% 0.83% 1.02% 1.1% - 1.23% 1.27% 1.19%
Announcement Date 30/03/20 26/03/21 29/03/22 30/03/23 26/03/24 - - -
1HKD in Million2HKD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for China Resources Pharmaceutical Group Limited

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.58 HKD
Average target price
7.424 HKD
Spread / Average Target
+33.05%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED Stock China Resources Pharmaceutical Group Limited
+8.77% 4.25B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.84% 698B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.56% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.34% 328B
ABBVIE INC. Stock AbbVie Inc.
+3.62% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.34% 238B
NOVARTIS AG Stock Novartis AG
+6.68% 203B
ROCHE HOLDING AG Stock Roche Holding AG
-9.08% 198B
AMGEN INC. Stock Amgen Inc.
+8.79% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 3320 Stock
  4. Financials China Resources Pharmaceutical Group Limited